loadpatents
Patent applications and USPTO patent grants for ASHIDA; Shinji.The latest application filed is for "antibody-pyrrolobenzodiazepine deprivative conjugate".
Patent | Date |
---|---|
Antibody-pyrrolobenzodiazepine Deprivative Conjugate App 20220168440 - TODA; Narihiro ;   et al. | 2022-06-02 |
X-ray diagnostic apparatus Grant 11,344,270 - Ashida , et al. May 31, 2 | 2022-05-31 |
Antibody-pyrrolobenzodiazepine Derivative Conjugate App 20220125943 - TODA; Narihiro ;   et al. | 2022-04-28 |
Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate Grant 11,261,261 - Naito , et al. March 1, 2 | 2022-03-01 |
(Anti-HER2 antibody)-drug conjugate Grant 11,185,594 - Naito , et al. November 30, 2 | 2021-11-30 |
Antibody-drug conjugate Grant 10,973,924 - Masuda , et al. April 13, 2 | 2021-04-13 |
Method Of Treating Cancer Comprising Administration Of Anti-her2 Antibody-drug Conjugate App 20200385486 - NAITO; Hiroyuki ;   et al. | 2020-12-10 |
Antibody-drug Conjugate App 20200282073 - MASUDA; Takeshi ;   et al. | 2020-09-10 |
Antibody-pyrrolobenzodiazepine Derivative Conjugate App 20200261594 - TODA; Narihiro ;   et al. | 2020-08-20 |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure Grant 10,729,782 - Naito , et al. | 2020-08-04 |
X-ray Diagnostic Apparatus App 20200205762 - ASHIDA; Shinji ;   et al. | 2020-07-02 |
X-ray diagnostic apparatus Grant 10,610,180 - Ashida , et al. | 2020-04-07 |
Anti-her2 Antibody-drug Conjugate App 20190077880 - NAITO; Hiroyuki ;   et al. | 2019-03-14 |
Antibody-drug conjugate Grant 10,195,288 - Masuda , et al. Fe | 2019-02-05 |
Antibody-drug Conjugate App 20190008981 - Masuda; Takeshi ;   et al. | 2019-01-10 |
Anti-HER2 antibody-drug conjugate Grant 10,155,821 - Naito , et al. Dec | 2018-12-18 |
Antibody-drug Conjugate Produced By Binding Through Linker Having Hydrophilic Structure App 20180071403 - NAITO; Hiroyuki ;   et al. | 2018-03-15 |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure Grant 9,872,924 - Naito , et al. January 23, 2 | 2018-01-23 |
Antibody-drug conjugate Grant 9,808,537 - Masuda , et al. November 7, 2 | 2017-11-07 |
(anti-her2 Antibody)-drug Conjugate App 20170035906 - NAITO; Hiroyuki ;   et al. | 2017-02-09 |
Anti-her2 Antibody-drug Conjugate App 20160333112 - NAITO; Hiroyuki ;   et al. | 2016-11-17 |
Antibody-drug Conjugate App 20160279259 - Masuda; Takeshi ;   et al. | 2016-09-29 |
Antibody-drug Conjugate Produced By Binding Through Linker Having Hydrophilic Structure App 20150352224 - NAITO; Hiroyuki ;   et al. | 2015-12-10 |
X-ray Diagnostic Apparatus App 20150325011 - ASHIDA; Shinji ;   et al. | 2015-11-12 |
Antibody-drug Conjugate App 20150297748 - MASUDA; Takeshi ;   et al. | 2015-10-22 |
Piperazinyl cyclohexane compounds as GPR38 agonists Grant 9,051,255 - Toda , et al. June 9, 2 | 2015-06-09 |
Cyclohexane Derivative Compound App 20140221391 - Toda; Narihiro ;   et al. | 2014-08-07 |
Cyclohexane Derivative Compound App 20140221392 - Toda; Narihiro ;   et al. | 2014-08-07 |
Piperazinyl methyl phenyl cyclohexane compound Grant 8,710,060 - Toda , et al. April 29, 2 | 2014-04-29 |
Cyclohexane Derivative Compound App 20130289048 - Toda; Narihiro ;   et al. | 2013-10-31 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.